1 |
Fogagnolo et al1616. Fogagnolo L, de Souza EM, Cintra ML, Velho PE. Vasculonecrotic reactions in leprosy. Braz J Infect Dis. 2007;11(3):378-82. |
Brazil |
2 |
Thalidomide 300mg/day, Prednisolone 80mg/day |
0 |
No-Not always mandatory |
2 |
Rahul nagar1717. Rahul N, Sanjay KS, Singh S. Effectiveness of Methotrexate in prednisolone and thalidomide resistant cases of Type 2 lepra reaction: report on three cases. Lepr Rev. 2015;86(4):379-82. |
India |
3 |
I- Prednisolone 40 mg/day |
1 |
Yes |
|
|
|
|
clofazimine 300 mgs/day |
|
|
|
|
|
|
thalidomide was tapered below 100 mgs/day. |
|
|
|
|
|
|
|
|
|
|
|
|
|
II- Prednisolone 40 mgs/day,clofazimine 100 mgs three times a day prednisolone in higher doses of 60 mgs/day. Two successive thalidomide courses were also found |
1 |
|
|
|
|
|
III- Prednisolone 40 mgs/day,clofazimine 100 mgs three times a day prednisolone in higher doses of 60 mgs/day. Two successive thalidomide courses were also found |
1 |
|
3 |
Rattan et al1818. Rattan R, Shanker V, Tegta GR, Verma GK. Severe form of type 2 reaction in patients of Hansen's disease after withdrawal of thalidomide: case reports. Indian J Lepr. 2009;81(4):199-203. |
India |
4 |
Thalidomide 100mg/thrice a day + MDT - MB |
0 |
No |
|
|
|
|
Thalidomide 100mg/thrice a day + MDT - MB Thalidomide 100mg/thrice a day + MDT - MB |
|
|
|
|
|
|
Thalidomide 100mg/thrice a day + MDT - MB |
|
|
4 |
Mahajan et al2121. Mahajan VK, Chauhan PS, Sharma NL, Sharma AL, Mehta KS. Severe vasculonecrotic erythema nodosum leprosum following thalidomide withdrawal without tapering doses: do we have something unusual?. Braz J Infect Dis . 2011;15(1):90-1. |
India |
1 |
Treatment restarted with prednisone (60 mg/day), clofazimine (100 mg three times/day), rifampicin (600 mg once a month), thalidomide (100 mg three times/day) |
1 |
Yes |
5 |
Jitendra ssv et al2222. Jitendra SSV, Bachaspatimayum R, Devi AS, Rita S. Azathioprine in Chronic Recalcitrant Erythema Nodosum Leprosum: A Case Report. J Clin Diagn Res. 2017;11(8):FD01-FD02. |
India |
1 |
Prednisolone 1 mg/kg/day |
1 |
Yes |
|
|
|
|
Clofazimine 300 mg/day for six months and 100 mg/day for another six months |
|
|
|
|
|
|
Thalidomide 200 mg/day (STOPPED) |
|
|
6 |
T . Narang et al2323. Narang T, Kaushik A, Dogra S. Apremilast in chronic recalcitrant erythema nodosum leprosum: A report of two cases. Br J Dermatol. 2019 Jun 19. doi: 10.1111/bjd.18233. [Epub ahead of print] https://doi.org/10.1111/bjd.18233...
|
India |
1 |
Started rationale dose but patient not tolerated (apremilast) |
1 |
Yes |
7 |
Barman et al2424. Barman KD, Madan A, Garg VK, Goel K, Khurana N. Unusual Presentation of Necrotic Erythema Nodosum Leprosum on Scalp: A Case Report. Indian J Lepr . 2015;87(1):23-6. |
India |
1 |
MDT, Thalidomide - 100mg, T. Prednisolone. |
0 |
No |
8 |
Richards2525. Lindsey E, Richards BS, Mary E, Horner AM. A Papulo-Nodular Eruption With Systemic Signs and Symptoms. J Drugs Dermatol. 2015;14(4):422-3. |
Pt from Micronesia- treated at Dallas, Texas |
1 |
MDT, Prednisolone 60mg/day, Thalidomide - 100mg |
0 |
No, Not always mandatory |
9 |
Rodriguez2626. Rodríguez G, Abaúnza MC, Vargas EJ, López F. Leprosy and the testis. Biomedica. 2012;32(1):13-22. |
Colombia |
1 |
MDT, Thalidomide 300mg/day, Prednisolone 50mg/day |
0 |
No, Not always mandatory |
10 |
Verma et al2727. Verma KK, Srivastava P, Minz A, Verma K. Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum. Lepr Rev. 2006;77(3):225-9. |
India |
1 |
MDT, Prednisolone 40mg/day, Thalidomide 100mg TDS, Azathiprine 50mg/twice daily. |
0 |
No |
11 |
Verma et al2727. Verma KK, Srivastava P, Minz A, Verma K. Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum. Lepr Rev. 2006;77(3):225-9. |
India |
1 |
MDT,Prednisolone 1mg/kg/day, Thallidomide 100mg QID for 4 months |
0 |
No |
12 |
Yogeesh HR et al2828. Hosahalli Rajaiah Yogeesh HR, Sujatha Chankramath,Hari Kishan Kumar Yadalla, Shameem Shariff,Suhas Bettadapura Ramesh, Sapnashree Budhnoor Sreekantaiah. Type 2 Lepra Reaction (Enl) Presenting With Extensive Cutaneous Ulcerations. Our Dermatol Online. 2012;3(1):17-20. |
India |
1 |
MDT, Prednisolone 30mg, Thalidomide 100mg TDS, |
0 |
No |
13 |
Faber et al2929. Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. 2006;355(7):739. |
Netherlands |
1 |
MDT, Steroids, Thalidomide 300mg, Pentoxiphylline 400mg, Finally, Infliximab 5mg/kg. |
0 |
No, Not always mandatory |
14 |
Hebe Petiti-Martin et al3030. Hebe Petiti-Martin G, Villar-Buill M, de la Hera I, Fuertes L, Burgués-Calderón M, Rivera-Díaz R, et al. Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction. Actas Dermosifiliogr. 2013;104(1):67-70. |
Spain |
1 |
MDT, Prednisolone, Thalidomide - 150mg/day [stopped], Enoxeparin, Acenocoumoral |
0 |
No, Not always mandatory |
15 |
Vetrichevel et al3131. Vetrichevvel TP, Pise GA, Thappa DM. A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. Lepr Rev. 2008;79(2):193-5. |
India |
1 |
MDT, Corticosteroids, Thalidomide 300mg/day then stopped, LMWheparin, Warfarin for 6 months. |
0 |
No |
16 |
Sundeep chowdary et al3232. Chaudhry NS, Rath SR, Visvanath V, Torsekar RG. Our experience of the use of thalidomide in the steroid-dependent severe erythema nodosum leprosum. Indian J Dermatol Venereol Leprol . 2009;75(2):189-90. |
India |
1 |
Prednisolone (40-80 mg) |
1 |
No |
|
|
|
|
Etanercept (50 mg / week) subcutaneously. |
|
|
|
|
|
|
Clofazimine (300 mg daily), |
|
|
|
|
|
|
Thalidomide (starting dose: 300 mg daily), |
|
|
|
|
|
|
Minocycline (100 mg daily), |
|
|
|
|
|
|
Clarithromycin (1 g daily), |
|
|
|
|
|
|
Ofloxacin (400 mg daily), |
|
|
|
|
|
|
Pentoxifylline (400 mg three times daily), |
|
|
|
|
|
|
Azathioprine (150 mg daily; later increased to 300 mg) |
|
|
17 |
Julia Rocha Silva Santos et al3333. Santos JRS, Vendramini DL, Nery JADC, Avelleira JCR. Etanercept in erythema nodosum leprosum. An Bras Dermatol. 2017;92(4):575-7. |
Brazi |
1 |
Thalidomide (100- 300 mg/day) |
0 |
No, Not always mandatory |
|
|
l |
|
prednisone at (20 - 40mg/day) |
|
|
|
|
|
|
50mg of etanercept SC. |
|
|
|
|
|
|
Thalidomide was interrupted |
|
|
|
|
|
|
Prednisone was continued at a dose of 10mg/day |
|
|
18 |
Gulanikar et al3434. Gulanikar AD, Sharma S, Khare A. Bullous Erythema Nodosum Leprosum: A Rare Entity. Indian J Lepr . 2018;90(3):245-8. |
India |
1 |
Prednisolone 30mg . Thalidomide 100mg QID |
0 |
No |
19 |
Yamaghuchi et al3535. Yamaguchi S, Yamamoto Y, Hosokawa A, Hagiwara K, Uezato H, Takahashi K. Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy. J Dermatol. 2012;39(8):711-4. |
Japan |
1 |
PSL 15-55 mg⁄ day,Thalidomide 100-300 mg⁄ day |
0 |
No, Not always mandatory |
20 |
Sharma et al3636. Sharma NL, Mahajan VK, Sharma VC, Sarin S, Sharma RC. Erythema nodosum leprosum and HIV infection: A therapeutic experience. Int J Lepr Other Mycobact Dis . 2005;73(3):189-93. |
India |
1 |
MDT |
0 |
No |
|
|
|
|
Prednisolone 60 mg/d, |
|
|
|
|
|
|
Ibuprofen 400 mg t.i.d. |
|
|
|
|
|
|
colchicine 0.5 mg b.i.d. |
|
|
|
|
|
|
thalidomide 100mg bd and stopped
|
|
|
Rationale with respect to use of thalidomide in planned dose: |
21 |
Satyendra Kumar Singh et al3737. Singh SK, Sharma T, Rai T, Prabhu A.Type 2 lepra reaction in an immunocompromised patient precipitated by filariasis. Indian J Sex Transm Dis AIDS. 2014;35(1):40-2. |
|
|
Plan for Thalidomide in desired rationale dose |
|
|
22 |
Prasan Kumar Panda et al3838. Panda PK, Prajapati R, Kumar A, Jana M, Immanuel P, Tanwar P, Wig N. A case of leprosy, erythema nodosum leprosum, and hemophagocytic syndrome: A continuum of manifestations of same agent-host interactions. Intractable & Rare Diseases Research. 2017;6(3):230-33. |
|
|
Plan for Thalidomide in desired rationale dose |
|
|